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nemia in Heart Failure
ime to Rethink Its
tiology and Treatment?*
. William Dec, MD, FACC
oston, Massachusetts
he occurrence of anemia (hemoglobin concentration
13.0 g/dl in men and 12.0 g/dl in women) in patients
ith chronic heart failure has recently received increased
ttention. Its prevalence ranges from 10% among patients
ith mild heart failure to more than 50% for those with
dvanced disease (1). A clinical profile of the anemic heart
ailure patient has gradually emerged. This individual tends
o be older; female; have more advanced symptoms and
igns of heart failure, has greater functional impairment and
igher hospitalization rates; and has a history of diabetes
ellitus, renal insufficiency, and hypertension (2). Anemic
atients also have lower peak oxygen consumption on
xercise testing compared with nonanemic patients (2).
See page 2485
Anemia has convincingly been shown to be a powerful
redictor of rehospitalization rates (3) and survival in
hronic heart failure (2–6). Most studies have shown a
inear relationship between hematocrit or hemoglobin and
urvival with the SOLVD (Studies of Left Ventricular
ysfunction) trial reporting a 2.7% increase in the adjusted
isk of death per 1% reduction in hematocrit and the
RAISE (Prospective Randomized Amlodipine Survival
valuation) trial describing a 3% increase in risk for each 1%
ecline in hematocrit (4,5).
The significance of anemia among patients hospital-
zed with acute decompensated heart failure also has been
xamined (7). Felker et al. (7) retrospectively analyzed
he OPTIME-CHF (Outcomes of a Prospective Trial of
ntravenous Milrinone for Exacerbations of Chronic
eart Failure) results and found that hemoglobin level
ndependently predicted adverse events, even after adjust-
ent for other covariates. For every 1 g/dl decrease in
dmission hemoglobin value, a 12% increase in the
robability of death or rehospitalization within 60 days of
reatment was observed. Recently, the same investigators
tudied anemia in patients with heart failure and pre-
erved systolic function (8). Anemia was once again
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.i
From the Cardiology Division, Massachusetts General Hospital, Boston, Massa-
husetts.ound to be independently associated with adverse out-
omes (adjusted hazard ratio: 1.6 to 1).
Why should anemia increase the risk of mortality in
atients with heart failure? Although most published re-
orts have not examined specific pathophysiologic mecha-
isms, a variety of plausible explanations exist. Anemia may
imply be a marker for other conventional factors that
ncrease mortality among patients with heart failure. For
xample, anemia often is associated with impaired renal
unction. This explanation seems unlikely because most
tudies have controlled for such comorbidities, including
enal dysfunction (2,3,6). Anemia also may be a marker for
igher circulating cytokines and chemokines, which are
nown to predict higher mortality in this population (6).
emodynamic changes accompanying severe anemia in-
lude increased preload, reduced peripheral vascular resis-
ance, and increased cardiac output. These adaptive re-
ponses may ultimately lead to a detrimental increase in left
entricular mass. Anand et al. (9) have reported that a 1 g/dl
ncrease in hemoglobin concentration is associated with a
.1 g/m2 decrease in left ventricular mass index during a
4-week period (9). Increased left ventricular mass consis-
ently has been demonstrated to be a significant factor for
oor prognosis (5,9). Myocardial ischemia also may be
recipitated from reduced oxygen-carrying capacity com-
ined with increased left ventricular mass and increased wall
tress. In addition, anemia has been shown to be associated
ith reversible elevations in plasma catecholamines and
lpha2-receptor densities among patients with renal failure.
inally, chronically increased myocardial work and adren-
rgic stimulation caused by decreased oxygen-carrying ca-
acity may ultimately lead to progression of heart failure and
ay accelerate adverse ventricular remodeling (4).
A variety of potential mechanisms may contribute to
nemia in heart failure (Table 1). It is highly likely that a
omplex interaction between impaired cardiac performance,
eurohormonal and inflammatory activation, renal dysfunc-
ion, and bone marrow hyporesponsiveness contribute to its
evelopment.
Expansion of plasma volume is common in heart failure;
ence, anemia may be dilutional rather than due to a true
ecrease in red cell mass. Androne et al. (10) reported that
emodilution accounted 46% of anemic heart failure pa-
ients. Circulating levels of erythropoietin are either normal
r mild/moderately elevated in chronic heart failure (8).
ncreased renal production of erythropoietin may be stim-
lated by renal hypoperfusion and hypoxia. Alternatively,
eart failure patients may have relative resistance to eryth-
opoietin due to the influence of pro-inflammatory cyto-
ines or malnutrition (6).
Circulating proinflammatory cytokines increase with disease
everity and predict worse clinical outcomes. Tumor necrosis
actor-alpha (TNF-), interleukin-1, and interleukin-6 have
irect effects on bone marrow function and have been
mplicated in the production of anemia of chronic disease
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December 19, 2006:2490–2 Editorial Comment6). Ezekowitz et al. (2) have reported that as many as 58%
f heart failure patients may have anemia of chronic disease.
n a murine model of heart failure, the number of bone
arrow progenitor cells and their proliferative capacity was
educed by 40% to 50% (6). A 3-fold increase in apoptosis
mong bone marrow progenitor cells was observed and
ignificantly correlated with increased TNF-/Fas expres-
ion (6). An inverse relationship between TNF- and
lasma hemoglobin levels has also been clinically demon-
trated (6). Thus, it is attractive to hypothesize that inflam-
atory activation may be an important contributor to
nemia in this population.
Iron deficiency is another potential cause of anemia in
atients with heart failure. Poor nutrition often is present in
dvanced disease and may curtail the absorption of dietary
ron. Gastrointestinal malabsorption, chronic aspirin use,
nd uremic gastritis may all precipitate iron deficiency
nemia. Ezekowitz et al. (2) have reported iron deficiency as
n etiology of anemia in 21% of their patients.
Finally, angiotensin-converting enzyme (ACE) inhibitor
herapy may reduce hemoglobin concentrations via de-
reased renal secretion of erythropoietin (6). van der Meer et
l. (11) have reported that the tetra-peptide, N-acetyl-seryl-
spartyl-lysyl-proline, an inhibitor of hematopoiesis and a
ubstrate for the ACE, is elevated in anemic patients
ompared with nonanemic heart failure patients and control
ubjects. Serum ACE activity was noted to be 73% lower in
he anemic heart failure patients and the serum of these
atients inhibited in vitro proliferation of bone marrow-
erived erythropoietic progenitor cells of healthy donors.
he clear correlation between N-acetyl-seryl-aspartyl-lysyl-
roline and proliferation of erythroid progenitor cell popu-
ations suggest an inhibitory role of this tetra-peptide on
ematopoiesis and could partially explain the observed
nemia during ACE inhibitor treatment. Some evidence
uggests that a decrease in hematocrit may be less pro-
ounced with angiotensin-receptor blockers.
This novel study by Nanas et al. (12) in this issue of the
ournal provides a new insight into the pathogenesis of heart
ailure-related anemia. The authors evaluated 37 consecu-
ive patients admitted with decompensated heart failure and
linically significant anemia. Patients with marked renal
ysfunction or concomitant diseases known to cause anemia
ere excluded. Intensive hematological evaluation in-
luded measurements of vitamin B12, folic acid, thyroid-
able 1. Potential Pathophysiological Mechanisms for Anemia
n Heart Failure
emodilutional effects
enal dysfunction with impaired erythropoietin production
roinflammatory cytokines
alnutrition
mpaired bone marrow function
ron deficiency
rug effects
nemia of chronic diseasetimulating hormone, erythropoietin, lactic dehydrogenase, doombs testing, multiple fecal occult tests, and bone
arrow aspiration. Patients without a diagnosis by these
ethods underwent red cell mass measurements by
hromium-51 assay. Unlike earlier reports, iron deficiency
nemia was confirmed by bone marrow aspiration in 27
atients (73%), 19% had anemia of chronic disease, and only
% had predominantly dilutional anemia. Although mean
orpuscular hemoglobin concentration was lower among
ron-deficient patients, neither serum iron nor ferritin levels
roved to be reliable markers of iron deficiency. Thus, the
uthors emphasized the need for bone marrow aspiration to
xclude iron deficiency among anemic heart failure patients.
lthough provocative, several methodologic limitations
ust be acknowledged. The number of patients evaluated
as quite small, and all had advanced decompensated
ymptoms. Unlike earlier published series, the mean age of
he population (58 years) was substantially younger than
ypical heart failure populations; more than 90% were men.
urther, only patients with previously undiagnosed anemia
ere included in this series. Finally, the true incidence of
emodilutional anemia cannot be estimated since only a
inority of patients underwent quantitative measurement of
ed cell mass.
Like all good studies, this report raises a number of
mportant questions. First, is a high prevalence of iron
eficiency simply characteristic of hospitalized patients with
ecompensated heart failure or may it also be a more
ommon underlying pathophysiologic mechanism among
mbulatory patients with New York Heart Association
NYHA) functional class II or III symptoms? Second, why
id this patient population not demonstrate the expected
ow serum ferritin concentration? It is possible that the
elative increase in ferritin may have been due to inflamma-
ory mediators that accompany the heart failure syndrome.
imilarly, the relatively low erythropoietin levels could
eflect cytokine inhibition of erythropoietin production.
hird, given the inaccuracy of serum hematologic measures,
hich anemic patients should be considered for bone
arrow aspiration in order to detect true iron deficiency?
inally, should our therapeutic approach to anemia among
eart failure patients also undergo re-evaluation? Recombi-
ant human erythropoietin has been studied in several small
eart failure cohorts (13,14). In an uncontrolled study by
ilverberg et al. (13), an improvement in ejection fraction,
YHA functional class, and hospitalization rates after
reatment with erythropoietin and intravenous iron replace-
ent was noted for patients with NYHA class III or IV
eart failure symptoms. Mancini et al. (14) have reported
rythropoietin-treated patients experienced significant im-
rovement in peak oxygen uptake in a randomized, single-
lind, placebo-controlled, 3-month trial of erythropoietin
herapy in anemic patients with advanced symptoms. Newer
rythropoietin analogs have been developed (such as
arbepoetin-) that have a longer half-life and require less
requent administration. An ongoing phase 2 clinical trial of
arbepoetin- in patients with heart failure should provide
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Editorial Comment December 19, 2006:2490–2mportant information on the potential efficacy of this new
gent. Despite its promise, erythropoietin is extremely
xpensive and it is often administered for only short periods
f time. If a sizable percentage of anemic patients are iron
eficient, the possibility of long-term oral or intermittent
ntravenous iron repletion may offer a more effective and
ower cost treatment alternative in this population. Prospec-
ive, randomized control trials of new therapeutic ap-
roaches to anemia in patients with heart failure are needed
nd may address the unanswered-but-crucial question of
hether correction of anemia will ultimately result in
mproved outcomes in this high-risk population.
eprint requests and correspondence: Dr. G. William Dec,
ardiology Division, Massachusetts General Hospital, Bigelow
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